Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.60 |
| ▸ | ITGB3 | P05106 | 12/20 | 0.60 |
| ▸ | ITGB5 | P18084 | 12/20 | 0.60 |
| ▸ | ITGB6 | P18564 | 11/20 | 0.60 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.60 |
| ▸ | ITGB8 | P26012 | 3/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17633617 | 0.86 | ITGAV (0.59) | ITGAVITGB3ITGB5ITGB6ITGB1 | |
| SCHEMBL17633618 | 0.86 | ITGAV (0.59) | ITGAVITGB3ITGB5ITGB6ITGB1 | |
| SCHEMBL20904207 | 0.86 | ITGAV (0.57) | ITGAVITGB3ITGB5ITGB6ITGB1 | |
| SCHEMBL19384558 | 0.86 | ITGAV (0.59) | ITGAVITGB3ITGB5ITGB6ITGB1 | |
| SCHEMBL22043499 | 0.84 | ITGAV (0.53) | ITGAVITGB3ITGB5ITGB6ITGB1 | |
| SCHEMBL19384603 | 0.83 | ITGAV (0.56) | ITGAVITGB3ITGB5ITGB6ITGB1 | |
| SCHEMBL19384509 | 0.83 | ITGAV (0.56) | ITGAVITGB3ITGB5ITGB6ITGB1 | |
| SCHEMBL19384511 | 0.83 | ITGAV (0.56) | ITGAVITGB3ITGB5ITGB6ITGB1 | |
| SCHEMBL22110205 | 0.82 | ITGAV (0.54) | ITGAVITGB3ITGB5ITGB6ITGB1 | |
| SCHEMBL29744295 | 0.81 | ITGAV (0.62) | ITGAVITGB3ITGB5ITGB6ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197894-B1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-03 | — | — | EP | disclosed |
| US-10513517-B2 | Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-12-24 | — | — | US | disclosed |
| US-20190048005-A1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-14 | — | — | US | disclosed |
| US-10144733-B2 | Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-12-04 | — | — | US | disclosed |
| US-20170291899-A1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10513517-B2 | Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases | ITGB1, ITGB3, ITGA1 | ITGAV 4/4885ITGB3 2/4885ITGB5 11/4885 |
| US-20170291899-A1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES | ITGB1, ITGB3, ITGA1 | ITGAV 4/4885ITGB3 2/4885ITGB5 11/4885 |
| US-20190048005-A1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES | ITGB1, ITGB3, ITGA1 | ITGAV 4/4885ITGB3 2/4885ITGB5 11/4885 |
| US-10144733-B2 | Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases | ITGB1, ITGB3, ITGA1 | ITGAV 4/4885ITGB3 2/4885ITGB5 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.